Pregnancy-specific malarial immunity and risk of malaria in pregnancy and adverse birth outcomes: a systematic review.
Antibodies
Epidemiology
Immunity
Malaria
Meta-analysis
Plasmodium falciparum
Pregnancy
Systematic review
Journal
BMC medicine
ISSN: 1741-7015
Titre abrégé: BMC Med
Pays: England
ID NLM: 101190723
Informations de publication
Date de publication:
16 01 2020
16 01 2020
Historique:
received:
24
06
2019
accepted:
11
11
2019
entrez:
17
1
2020
pubmed:
17
1
2020
medline:
21
10
2020
Statut:
epublish
Résumé
In endemic areas, pregnant women are highly susceptible to Plasmodium falciparum malaria characterized by the accumulation of parasitized red blood cells (pRBC) in the placenta. In subsequent pregnancies, women develop protective immunity to pregnancy-associated malaria and this has been hypothesized to be due to the acquisition of antibodies to the parasite variant surface antigen VAR2CSA. In this systematic review we provide the first synthesis of the association between antibodies to pregnancy-specific P. falciparum antigens and pregnancy and birth outcomes. We conducted a systematic review and meta-analysis of population-based studies (published up to 07 June 2019) of pregnant women living in P. falciparum endemic areas that examined antibody responses to pregnancy-specific P. falciparum antigens and outcomes including placental malaria, low birthweight, preterm birth, peripheral parasitaemia, maternal anaemia, and severe malaria. We searched 6 databases and identified 33 studies (30 from Africa) that met predetermined inclusion and quality criteria: 16 studies contributed estimates in a format enabling inclusion in meta-analysis and 17 were included in narrative form only. Estimates were mostly from cross-sectional data (10 studies) and were heterogeneous in terms of magnitude and direction of effect. Included studies varied in terms of antigens tested, methodology used to measure antibody responses, and epidemiological setting. Antibody responses to pregnancy-specific pRBC and VAR2CSA antigens, measured at delivery, were associated with placental malaria (9 studies) and may therefore represent markers of infection, rather than correlates of protection. Antibody responses to pregnancy-specific pRBC, but not recombinant VAR2CSA antigens, were associated with trends towards protection from low birthweight (5 studies). Whilst antibody responses to several antigens were positively associated with the presence of placental and peripheral infections, this review did not identify evidence that any specific antibody response is associated with protection from pregnancy-associated malaria across multiple populations. Further prospective cohort studies using standardized laboratory methods to examine responses to a broad range of antigens in different epidemiological settings and throughout the gestational period, will be necessary to identify and prioritize pregnancy-specific P. falciparum antigens to advance the development of vaccines and serosurveillance tools targeting pregnant women.
Sections du résumé
BACKGROUND
In endemic areas, pregnant women are highly susceptible to Plasmodium falciparum malaria characterized by the accumulation of parasitized red blood cells (pRBC) in the placenta. In subsequent pregnancies, women develop protective immunity to pregnancy-associated malaria and this has been hypothesized to be due to the acquisition of antibodies to the parasite variant surface antigen VAR2CSA. In this systematic review we provide the first synthesis of the association between antibodies to pregnancy-specific P. falciparum antigens and pregnancy and birth outcomes.
METHODS
We conducted a systematic review and meta-analysis of population-based studies (published up to 07 June 2019) of pregnant women living in P. falciparum endemic areas that examined antibody responses to pregnancy-specific P. falciparum antigens and outcomes including placental malaria, low birthweight, preterm birth, peripheral parasitaemia, maternal anaemia, and severe malaria.
RESULTS
We searched 6 databases and identified 33 studies (30 from Africa) that met predetermined inclusion and quality criteria: 16 studies contributed estimates in a format enabling inclusion in meta-analysis and 17 were included in narrative form only. Estimates were mostly from cross-sectional data (10 studies) and were heterogeneous in terms of magnitude and direction of effect. Included studies varied in terms of antigens tested, methodology used to measure antibody responses, and epidemiological setting. Antibody responses to pregnancy-specific pRBC and VAR2CSA antigens, measured at delivery, were associated with placental malaria (9 studies) and may therefore represent markers of infection, rather than correlates of protection. Antibody responses to pregnancy-specific pRBC, but not recombinant VAR2CSA antigens, were associated with trends towards protection from low birthweight (5 studies).
CONCLUSIONS
Whilst antibody responses to several antigens were positively associated with the presence of placental and peripheral infections, this review did not identify evidence that any specific antibody response is associated with protection from pregnancy-associated malaria across multiple populations. Further prospective cohort studies using standardized laboratory methods to examine responses to a broad range of antigens in different epidemiological settings and throughout the gestational period, will be necessary to identify and prioritize pregnancy-specific P. falciparum antigens to advance the development of vaccines and serosurveillance tools targeting pregnant women.
Identifiants
pubmed: 31941488
doi: 10.1186/s12916-019-1467-6
pii: 10.1186/s12916-019-1467-6
pmc: PMC6964062
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
14Subventions
Organisme : National Health and Medical Research Council (AU)
ID : 1166753
Pays : International
Organisme : National Health and Medical Research Council
ID : 1104975
Pays : International
Organisme : Australian Centre of Research Excellence in Malaria Elimination (ACREME)
ID : 1134989
Pays : International
Organisme : Australian Centre of Research Excellence in Malaria Elimination (ACREME)
ID : 1134989
Pays : International
Organisme : Australian Research Council
ID : FT130101122
Pays : International
Références
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
J Infect Dis. 2016 Aug 15;214(4):577-86
pubmed: 27190180
PLoS One. 2014 Feb 04;9(2):e88173
pubmed: 24505415
Infect Immun. 2018 Aug 22;86(9):
pubmed: 29986889
PLoS Pathog. 2016 Aug 24;12(8):e1005831
pubmed: 27556547
Malar J. 2004 Jul 08;3:21
pubmed: 15242514
J Infect Dis. 2014 Nov 1;210(9):1444-55
pubmed: 24799599
Am J Trop Med Hyg. 1996 Jul;55(1):76-80
pubmed: 8702026
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120
Infect Immun. 1999 Oct;67(10):5367-71
pubmed: 10496918
Trends Parasitol. 2019 Sep;35(9):677-686
pubmed: 31395496
Am J Pathol. 1982 Dec;109(3):330-42
pubmed: 6758604
Lancet Infect Dis. 2007 Feb;7(2):105-17
pubmed: 17251081
Malar J. 2017 Sep 29;16(1):391
pubmed: 28962616
Infect Immun. 2001 Dec;69(12):7487-92
pubmed: 11705924
Mol Biochem Parasitol. 2006 Aug;148(2):117-24
pubmed: 16631964
Infect Immun. 1997 Apr;65(4):1251-7
pubmed: 9119459
Infect Immun. 2014 Nov;82(11):4842-53
pubmed: 25156731
Infect Immun. 2010 May;78(5):1963-78
pubmed: 20160014
PLoS One. 2010 Feb 16;5(2):e9230
pubmed: 20169064
Vaccine. 2017 Jun 14;35(27):3474-3481
pubmed: 28527688
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):5198-202
pubmed: 10220443
J Infect Dis. 2012 Nov 15;206(10):1612-21
pubmed: 22966126
Lancet Infect Dis. 2012 May;12(5):388-96
pubmed: 22169409
J Infect Dis. 1999 Aug;180(2):464-72
pubmed: 10395863
Vaccine. 2012 Feb 8;30(7):1343-8
pubmed: 22226864
Am J Trop Med Hyg. 2003 Jan;68(1):115-9
pubmed: 12556159
PLoS One. 2010 May 25;5(5):e10807
pubmed: 20520838
Anat Rec. 1984 Nov;210(3):477-84
pubmed: 6084429
Nature. 1998 Oct 29;395(6705):851-2
pubmed: 9804416
Lancet Infect Dis. 2007 Feb;7(2):93-104
pubmed: 17251080
PLoS One. 2011;6(7):e22491
pubmed: 21811621
Lancet Glob Health. 2017 Nov;5(11):e1101-e1112
pubmed: 28967610
PLoS One. 2012;7(6):e40049
pubmed: 22761948
Sci Rep. 2018 Oct 18;8(1):15429
pubmed: 30337594
Trends Parasitol. 2014 Feb;30(2):85-94
pubmed: 24388420
Lancet. 2004 Jan 24;363(9405):283-9
pubmed: 14751701
Infect Immun. 2003 Nov;71(11):6620-3
pubmed: 14573685
J Infect Dis. 2009 Jul 15;200(2):299-306
pubmed: 19500037
Malar J. 2008 Jan 11;7:10
pubmed: 18190692
Science. 1996 Jun 7;272(5267):1502-4
pubmed: 8633247
Am J Trop Med Hyg. 1996;55(1 Suppl):24-32
pubmed: 8702034
Br Med J (Clin Res Ed). 1983 Jul 23;287(6387):251-4
pubmed: 6409270
J Infect Dis. 2014 May 1;209(9):1408-17
pubmed: 24277742
Mol Microbiol. 2003 Jul;49(1):179-91
pubmed: 12823820
J Immunol. 2013 Jul 15;191(2):795-809
pubmed: 23776179
Trop Med Int Health. 2001 Oct;6(10):770-8
pubmed: 11679125
J Infect Dis. 2010 Jan 1;201(1):123-31
pubmed: 19954383
J Exp Med. 1995 Jul 1;182(1):15-20
pubmed: 7790815
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
Am J Surg Pathol. 1998 Aug;22(8):1006-11
pubmed: 9706981
Malar J. 2015 Dec 01;14:480
pubmed: 26626275
J Infect Dis. 2007 Jul 1;196(1):155-64
pubmed: 17538896
Infect Immun. 2005 Jul;73(7):4112-8
pubmed: 15972500
J Eval Clin Pract. 2008 Oct;14(5):951-7
pubmed: 19018930
Vaccine. 2015 Dec 22;33(52):7483-8
pubmed: 26469717
PLoS One. 2007 Sep 19;2(9):e910
pubmed: 17878945
Cold Spring Harb Perspect Med. 2017 Jun 1;7(6):null
pubmed: 28213434
PLoS One. 2017 Oct 13;12(10):e0186577
pubmed: 29028827
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
Trans R Soc Trop Med Hyg. 1983;77(2):232-44
pubmed: 6346592
J Infect Dis. 2013 Jun 1;207(11):1664-74
pubmed: 23448726
PLoS Med. 2010 Jan 19;7(1):e1000218
pubmed: 20098724
Malar J. 2016 Nov 9;15(1):547
pubmed: 27829430
Placenta. 2004 May;25(5):359-78
pubmed: 15081631
Parasite Immunol. 2006 Jan-Feb;28(1-2):51-60
pubmed: 16438676
J Infect Dis. 2004 Feb 1;189(3):540-51
pubmed: 14745713
Expert Opin Biol Ther. 2015;15(8):1173-82
pubmed: 26051589
Infect Immun. 2018 Jul 23;86(8):
pubmed: 29784859
J Immunol. 2000 Sep 15;165(6):3309-16
pubmed: 10975848
Infect Immun. 2005 May;73(5):2841-7
pubmed: 15845489
J Infect Dis. 2010 May 1;201(9):1316-25
pubmed: 20350189
Emerg Infect Dis. 2015 May;21(5):813-23
pubmed: 25898123
J Infect Dis. 2011 Oct 1;204(7):1125-33
pubmed: 21881129
J Infect Dis. 2006 Mar 1;193(5):713-20
pubmed: 16453268
J Exp Med. 2004 Nov 1;200(9):1197-203
pubmed: 15520249
JAMA. 1998 Nov 18;280(19):1690-1
pubmed: 9832001
J Infect Dis. 2001 Sep 1;184(5):618-26
pubmed: 11494167
Infect Immun. 2011 Apr;79(4):1654-9
pubmed: 21300778
J Mol Biol. 2010 Apr 2;397(3):826-34
pubmed: 20109466
Lancet Infect Dis. 2016 May;16(5):576-583
pubmed: 26869377
Infect Immun. 2012 Apr;80(4):1479-90
pubmed: 22331427
J Biol Chem. 2012 Jul 6;287(28):23332-45
pubmed: 22570492
PLoS One. 2011;6(5):e20270
pubmed: 21625526
Malar J. 2018 Mar 9;17(1):106
pubmed: 29523137
Infect Immun. 2014 Jun;82(6):2565-73
pubmed: 24686068